Почетна › Рак на бели дробови со не-мали клетки › Мејн

Клинички испитувања за Рак на бели дробови со не-мали клетки во Мејн

16 студии за Рак на бели дробови со не-мали клетки бараат учесници на локации во Мејн.

Градови во Мејн

Официјален текст на студијата (англиски)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
Lafayette Family Cancer Center-EMMC, Brewer
и уште 5

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

MaineHealth Coastal Cancer Treatment Center, Bath
MaineHealth Cancer Care and IV Therapy - Brunswick, Brunswick
MaineHealth Maine Medical Center - Portland, Portland
и уште 3

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07293247

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

New England Cancer Specialists ( Site 0139), Westbrook

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Maine Medical Center- Scarborough, Scarborough
MaineHealth Cancer Care and IV Therapy - South Portland, South Portland

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06498635

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

New England Cancer Specialists ( Site 0095), Westbrook

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06312137

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Maine Medical Center, Portland
MaineHealth Cancer Care and Blood Disorders Scarborough, Scarborough
MaineHealth Cancer Care and IV Therapy - South Portland, South Portland

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06758401

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

New England Cancer Specialists ( Site 0143), Westbrook

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06170788

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

New England Cancer Specialists, Westbrook

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT06890598

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Scarborough

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT06692738

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, South Portland

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT07291037

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 3.6.2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 6.5.2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

Се регрутираФаза 2

18 Minutes · Сите полови · Ажурирано 5.5.2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
Lafayette Family Cancer Center-EMMC, Brewer
и уште 5

Се регрутираФаза 2/3

Возраст 18 и постари · Сите полови · Ажурирано 5.5.2026 · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
MaineHealth Maine Medical Center - Biddeford, Biddeford
и уште 7

Се регрутираНабљудувачка студија

Возраст 18 и постари · Сите полови · Ажурирано 17.3.2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Scarborough

Се регрутираНабљудувачка студија

Сите возрасти · Сите полови · Ажурирано 28.10.2025 · NCT03452774

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.